{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:35:26Z","timestamp":1784903726385,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"am","delay-in-days":342,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014369","name":"Organon BioSciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014369","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Organon Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["59518"],"award-info":[{"award-number":["59518"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001082"],"award-info":[{"award-number":["UL1 TR001082"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["5K12HD001271-18"],"award-info":[{"award-number":["5K12HD001271-18"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.contraception.2023.110035","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T12:43:20Z","timestamp":1680007400000},"page":"110035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0208-8432","authenticated-orcid":false,"given":"Aaron","family":"Lazorwitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanelle","family":"Sheeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Teal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2023.110035_bib1","unstructured":"Treatment Regimens for Latent TB Infection (LTBI). Centers for Disease Control and Prevention; 2020."},{"key":"10.1016\/j.contraception.2023.110035_bib2","unstructured":"U.S. Food and Drug Administration. Drug Development and Drug Interactions: Table of Substrates, Inhibitors, and Inducers 2022."},{"key":"10.1016\/j.contraception.2023.110035_bib3","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/1471-0528.15027","article-title":"Drug interactions between rifamycin antibiotics and hormonal contraception: a systematic review","volume":"125","author":"Simmons","year":"2018","journal-title":"BJOG"},{"key":"10.1016\/j.contraception.2023.110035_bib4","first-page":"1","article-title":"U.S. Medical Eligibility Criteria for contraceptive use, 2016","volume":"65","author":"Curtis","year":"2016","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.contraception.2023.110035_bib5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.contraception.2017.03.004","article-title":"The effect of carbamazepine on etonogestrel concentrations in contraceptive implant users","volume":"95","author":"Lazorwitz","year":"2017","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2023.110035_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40834-022-00172-1","article-title":"Etonogestrel contraceptive implant failure in a woman taking rifampin: a case report","volume":"7","author":"Tufa","year":"2022","journal-title":"Contracept Reprod Med"},{"key":"10.1016\/j.contraception.2023.110035_bib7","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1345\/aph.10149","article-title":"Implanon: a critical review","volume":"35","author":"Le","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.contraception.2023.110035_bib8","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/FTD.0b013e31829a10fa","article-title":"A UPLC-MS\/MS method for therapeutic drug monitoring of etonogestrel","volume":"35","author":"Thomas","year":"2013","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.contraception.2023.110035_bib9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.contraception.2019.03.045","article-title":"Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users","volume":"100","author":"Lazorwitz","year":"2019","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2023.110035_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.contraception.2023.110035_bib11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0015-0282(16)46095-4","article-title":"The value of a single serum progesterone measurement in the midluteal phase as a criterion of a potentially fertile cycle (\"ovulation\") derived form treated and untreated conception cycles","volume":"37","author":"Hull","year":"1982","journal-title":"Fertil Steril"},{"key":"10.1016\/j.contraception.2023.110035_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF00563105","article-title":"The effect of rifampicin on norethisterone pharmacokinetics","volume":"15","author":"Back","year":"1979","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.contraception.2023.110035_bib13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0010-7824(80)90125-0","article-title":"The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women","volume":"21","author":"Back","year":"1980","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2023.110035_bib14","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0009-9236(99)70138-4","article-title":"The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive","volume":"65","author":"Barditch-Crovo","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.contraception.2023.110035_bib15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.contraception.2012.01.010","article-title":"Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women","volume":"86","author":"Blode","year":"2012","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2023.110035_bib16","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/009127009803801109","article-title":"Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone","volume":"38","author":"LeBel","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.contraception.2023.110035_bib17","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/clpt.1990.92","article-title":"A model to detect interactions between roxithromycin and oral contraceptives","volume":"47","author":"Meyer","year":"1990","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.contraception.2023.110035_bib18","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/0010-7824(80)90034-7","article-title":"A study of interaction of a low-dose combination oral contraceptive with anti-tubercular drugs","volume":"21","author":"Joshi","year":"1980","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2023.110035_bib19","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1097\/QAD.0000000000001591","article-title":"Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy","volume":"31","author":"Chappell","year":"2017","journal-title":"AIDS (London, England)"},{"key":"10.1016\/j.contraception.2023.110035_bib20","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/QAI.0000000000000189","article-title":"Effect of antiretroviral therapy including lopinavir\/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women","volume":"66","author":"Vieira","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.contraception.2023.110035_bib21","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1016\/S2352-3018(15)00184-8","article-title":"Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study","volume":"2","author":"Patel","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.contraception.2023.110035_bib22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1752-1947-8-43","article-title":"Decreased efficacy of an etonogestrel implant in a woman on antiepileptic medications: a case report","volume":"8","author":"Lange","year":"2014","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.contraception.2023.110035_bib23","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.contraception.2005.12.012","article-title":"Ovarian cysts in users of Implanon and Jadelle subdermal contraceptive implants","volume":"73","author":"Hidalgo","year":"2006","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2023.110035_bib24","series-title":"Contraceptive\u00a0technology","author":"Hatcher","year":"2018"},{"key":"10.1016\/j.contraception.2023.110035_bib25","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/AOG.0000000000003189","article-title":"Influence of genetic variants on steady-state etonogestrel concentrations among contraceptive implant users","volume":"133","author":"Lazorwitz","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2023.110035_bib26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.contraception.2021.12.008","article-title":"Variability in repeat serum etonogestrel concentrations among contraceptive implant users during the steady-release pharmacokinetic period","volume":"108","author":"Lazorwitz","year":"2022","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2023.110035_bib27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bcp.12441","article-title":"Addressing phenoconversion: the Achilles' heel of personalized medicine","volume":"79","author":"Shah","year":"2015","journal-title":"Br J Clin Pharmacol"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782423001038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782423001038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T08:59:01Z","timestamp":1769763541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782423001038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":27,"alternative-id":["S0010782423001038"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2023.110035","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2023.110035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110035"}}